Atea Pharmaceuticals(AVIR)
$3.93-0.06 (-1.50%)
AVIR
Atea Pharmaceuticals financials statements
$3.93
At close:-0.06 (-1.50%)
Want to see AVIR full AI Analyst Report?
Atea Pharmaceuticals (AVIR) Ratios
248 Followers
Atea Pharmaceuticals Ratios
AVIR's free cash flow for Q3 2026 was $-28.87M. For the 2026 fiscal year, AVIR's free cash flow was increased by $0.00 and operating cash flow was $-28.87M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.82 | 24.85 | 18.24 | 35.77 | 13.58 |
| Quick Ratio | 7.82 | 24.85 | 18.24 | 35.77 | 13.58 |
| Cash Ratio | 2.41 | 3.48 | 4.44 | 35.00 | 13.44 |
| Solvency Ratio | -3.97 | -6.51 | -3.41 | -4.42 | 1.93 |
| Operating Cash Flow Ratio | -3.32 | -7.28 | -2.64 | -6.55 | -1.53 |
| Short-Term Operating Cash Flow Coverage | -156.62 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 271.21M | $ 436.55M | $ 550.68M | $ 634.79M | $ 709.59M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.14 | 1.06 | 1.07 | 1.04 | 1.09 |
| Debt Service Coverage Ratio | -187.35 | 0.00 | 0.00 | -9.62 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -11.72 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.02 | 0.03 | 0.17 | 0.00 |
| Net Debt to EBITDA | 0.58 | 0.48 | 1.18 | 5.81 | -5.52 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 52.41% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 39.38% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 39.39% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 39.38% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 39.44% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 34.49% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 34.49% |
| Net Income Per EBT | 96.25% | 100.55% | 100.75% | 97.00% | 87.44% |
| EBT Per EBIT | 90.95% | 86.79% | 82.20% | 91.46% | 100.15% |
| Return on Assets (ROA) | -50.23% | -36.24% | -22.85% | -17.39% | 15.68% |
| Return on Equity (ROE) | -57.49% | -38.37% | -24.49% | -18.09% | 17.07% |
| Return on Capital Employed (ROCE) | -65.67% | -43.26% | -29.18% | -20.15% | 19.33% |
| Return on Invested Capital (ROIC) | -63.02% | -43.18% | -29.14% | -19.53% | 16.90% |
| Return on Tangible Assets | -50.23% | -36.24% | -22.85% | -17.39% | 15.68% |
| Earnings Yield | -54.43% | -59.65% | -53.45% | -28.95% | 16.37% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 18.70 | 16.48 | 24.46 | 36.88 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 1909.60 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.45 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 |
| Cash Conversion Cycle | 0.00 | -19.52 | -22.14 | -14.92 | -9.90 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 19.52 | 22.14 | 14.92 | 9.90 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.62 | -1.61 | -1.02 | -1.45 | -1.05 |
| Free Cash Flow Per Share | -1.62 | -1.61 | -1.02 | -1.48 | -1.05 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | -62.27 | -21751.25 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | -62.27 | -21751.25 |
| Operating Cash Flow Coverage Ratio | -156.62 | -82.52 | -35.55 | -38.73 | -441.65 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.25 |
| Free Cash Flow Yield | -45.38% | -48.00% | -33.58% | -30.70% | -11.75% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.84 | -1.68 | -1.87 | -3.45 | 6.11 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 2.11 |
| Price-to-Book (P/B) Ratio | 1.06 | 0.64 | 0.46 | 0.63 | 1.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.20 | -2.08 | -2.98 | -3.26 | -8.51 |
| Price-to-Operating Cash Flow Ratio | -2.20 | -2.08 | -2.98 | -3.31 | -8.51 |
| Price-to-Earnings Growth (PEG) Ratio | 0.61 | -0.07 | -0.11 | 0.02 | -0.00 |
| Enterprise Value Multiple | -1.19 | -1.66 | -0.94 | 2.19 | -0.17 |
| Enterprise Value | 196.07M | 219.23M | 112.92M | -243.17M | -23.77M |
| EV to EBITDA | -1.19 | -1.66 | -0.94 | 2.19 | -0.17 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | -0.07 |
| EV to Free Cash Flow | -1.49 | -1.62 | -1.32 | 1.98 | 0.27 |
| EV to Operating Cash Flow | -1.49 | -1.62 | -1.32 | 2.01 | 0.27 |
| Tangible Book Value Per Share | 3.38 | 5.21 | 6.66 | 7.69 | 8.57 |
| Shareholders’ Equity Per Share | 3.38 | 5.21 | 6.66 | 7.69 | 8.57 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.04 | -0.01 | -0.01 | 0.03 | 0.13 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 4.24 |
| Net Income Per Share | -1.94 | -2.00 | -1.63 | -1.39 | 1.46 |
| Tax Burden | 0.96 | 1.01 | 1.01 | 0.97 | 0.87 |
| Interest Burden | 1.00 | 1.27 | 1.12 | 1.08 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 |
| Income Quality | 0.83 | 0.80 | 0.63 | 1.04 | -0.72 |
Currency in USD

